BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17327288)

  • 1. Nesiritide compared with milrinone for cardiac surgery.
    Blais DM
    Ann Pharmacother; 2007 Mar; 41(3):502-4. PubMed ID: 17327288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients.
    Brackbill ML; Stam MD; Schuller-Williams RV; Dhavle AA
    Ann Pharmacother; 2007 Mar; 41(3):427-32. PubMed ID: 17311834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
    Simkova V; Radermacher P; Barth E
    Crit Care; 2007; 11(3):139. PubMed ID: 17572916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination therapy with PDE III inhibitor for heart failure].
    Watanabe H; Kajimoto K; Kawana M
    Nihon Rinsho; 2007 May; 65 Suppl 5():134-9. PubMed ID: 17571377
    [No Abstract]   [Full Text] [Related]  

  • 6. Nesiritide: first use in India.
    Manchanda A; Kohli V
    Indian Heart J; 2009; 61(4):371-2. PubMed ID: 20635741
    [No Abstract]   [Full Text] [Related]  

  • 7. Nesiritide as bridge to multi-organ transplantation: a case report.
    Cochrane AB; Fedson SE; Cronin DC
    Transplant Proc; 2007; 39(1):308-10. PubMed ID: 17275531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery].
    Hibino N; Tomino T; Satoh H; Hamawaki M; Imura M; Suzuki T; Inukai M
    Kyobu Geka; 2000 Nov; 53(12):1019-23. PubMed ID: 11079307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery.
    Ejaz AA; Martin TD; Johnson RJ; Winterstein AG; Klodell CT; Hess PJ; Ali AK; Whidden EM; Staples NL; Alexander JA; House-Fancher MA; Beaver TM
    J Thorac Cardiovasc Surg; 2009 Oct; 138(4):959-64. PubMed ID: 19660420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nesiritide: harmful or harmless?
    Dorsch MP; Rodgers JE
    Pharmacotherapy; 2006 Oct; 26(10):1465-78. PubMed ID: 16999657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
    Saltzberg MT
    Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of nesiritide in pediatric heart failure.
    Jefferies JL; Price JF; Denfield SW; Chang AC; Dreyer WJ; McMahon CJ; Grenier MA; Clunie SK; Thomas A; Moffett BS; Wann TS; Smith EO; Towbin JA
    J Card Fail; 2007 Sep; 13(7):541-8. PubMed ID: 17826644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary experience with nesiritide in the pediatric population.
    Marshall J; Berkenbosch JW; Russo P; Tobias JD
    J Intensive Care Med; 2004; 19(3):164-70. PubMed ID: 15154997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of phosphodiesterase type III before aortic cross-clamping preserves intramyocardial cyclic adenosine monophosphate during cardiopulmonary bypass.
    Janelle GM; Urdaneta F; Blas ML; Shryock J; Tang YS; Martin TD; Lobato EB
    Anesth Analg; 2001 Jun; 92(6):1377-83. PubMed ID: 11375808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
    Gold J; Cullinane S; Chen J; Seo S; Oz MC; Oliver JA; Landry DW
    Am J Cardiol; 2000 Feb; 85(4):506-8, A11. PubMed ID: 10728962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nesiritide in acute heart failure.
    Burger AJ; Silver MA
    Lancet; 2003 Sep; 362(9388):998; author reply 998-9. PubMed ID: 14511939
    [No Abstract]   [Full Text] [Related]  

  • 18. Short and long-term mortality with nesiritide.
    Arora RR; Venkatesh PK; Molnar J
    Am Heart J; 2006 Dec; 152(6):1084-90. PubMed ID: 17161057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide in acute heart failure.
    Drazner M; McGuire DK; de Lemos JA
    Lancet; 2003 Sep; 362(9388):998-9. PubMed ID: 14511940
    [No Abstract]   [Full Text] [Related]  

  • 20. Natriuretic peptides in the perioperative management of cardiac surgery patients.
    Moazami N; Oz MC
    Heart Surg Forum; 2005; 8(3):E151-7. PubMed ID: 16183564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.